CAMBRIDGE, Mass., Nov. 08, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of migraine in adults, with or without aura, announced today it will provide a corporate overview at the Stifel 2016 Healthcare Conference, being held on November 15-16 in New York City.

Stifel 2016 Healthcare Conference
Date: Tuesday, November 15
Time: 2:15pm Eastern Time
Location: The Lotte New York Palace Hotel, Holmes I Room
Webcast: http://wsw.com/webcast/stifel5/clcd

About CoLucid Pharmaceuticals, Inc.
CoLucid is developing lasmiditan oral tablets for the acute treatment of migraine headaches in adults and intravenous lasmiditan for the acute treatment of headache pain associated with migraine in adults in emergency room and other urgent care settings.

CONTACT
Thomas Mathers                      
Chief Executive Officer           
CoLucid Pharmaceuticals, Inc.
(857) 285-6494

Hans Vitzthum
Managing Director
LifeSci Advisors, LLC.
(212) 915-2568

Primary Logo